Acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, and selinexor, a selective inhibitor of nuclear export (SINE) acting via NF-κB inactivation, are currently being evaluated in COVID-19 clinical trials [150,151,152,153]. The gene discussed is NFKB1; the disease is COVID-19.